Targeting the PI3K/AKT/mTOR pathway using a PI3K inhibitor (e.g., alpelisib) and mTOR inhibitor (e.g., everolimus) is a standard therapeutic strategy for HR-positive, HER2-negative IBC-NSTs. Here, MTOR is linked to inflammatory breast carcinoma.